Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule
or Standard; Transfer of Listing.
On April 25, 2023, Evelo Biosciences, Inc. received a letter
from the Listing. | May 1, 2023
Item 8.01 Other Events.
As previously disclosed in the Current Report on Form 8-K of Better
Therapeutics, Inc. filed with the Securities and Exchange
Commission on April 7, 2023, the Company. | April 24, 2023
The following discussion and analysis of the Company s financial condition and
results of operations should be read in conjunction with the financial
statements and the notes thereto contained. | April 17, 2023
14.04.2023 - CHASKA, Minn., April 14, 2023 (GLOBE NEWSWIRE) - Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on April 13, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market .
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On April 11, 2023, TKB Critical Technologies 1 received a letter from the Listing. | April 14, 2023